Genetic Engineering and Biotechnology News
HIV research has reached the point that a cure may be possible. “HIV is a complicated disease, and it’s very encouraging to see advancements,” says Elizabeth Wolffe, Ph.D., Sangamo BioSciences spokesperson. “We’ve seen antiretroviral therapies that have made HIV a chronic disease. Now we’re starting to envision strategies to arm the body’s immune system to fight the virus. The industry is beginning to embrace the idea of cure strategies.”
Frost & Sullivan predicts a compound annual growth rate (CAGR) of 7.5% between 2012 and 2019, with 2012 sales estimated at $5.58 billion for Europe. Globally, BCC Research predicts market growth for HIV therapeutics at 4.6%. It projects global sales of $14.1 billion in 2016. Branded HIV products were expected to account for $13.2 billion of that. Generics, particularly in the developing world, make up the difference and are projected to grow commensurately.
Continued . . .